Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + Vecuronium
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Reversal of Neuromuscular Blockade
Conditions
Reversal of Neuromuscular Blockade
Trial Timeline
Dec 20, 2017 → Sep 4, 2019
NCT ID
NCT03346057About Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + Vecuronium
Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + Vecuronium is a approved stage product being developed by Merck for Reversal of Neuromuscular Blockade. The current trial status is completed. This product is registered under clinical trial identifier NCT03346057. Target conditions include Reversal of Neuromuscular Blockade.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03346057 | Approved | Completed |
Competing Products
3 competing products in Reversal of Neuromuscular Blockade
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sugammadex + Neostigmine | Merck | Approved | 85 |
| Beriplex® P/N (Kcentra) + Fresh frozen plasma | CSL | Phase 3 | 76 |
| Beriplex | CSL | Phase 2 | 51 |